Ona Therapeutics to develop ADC with WuXi’s payload-linker platform
The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with
The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier’s clinical activities
The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is designed for